# EDGAR Filing Document

**Accession Number:** 0001618835
**File Stem:** 0001493152-26-020417
**Filing Date:** 2026-4
**Character Count:** 77092
**Document Hash:** e09cb8bb4704adbd14a6d8c20dcb1e5c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-020417.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001493152-26-020417

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260424

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evofem Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001618835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208527075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36754
- **FILM NUMBER:** 26925046

**BUSINESS ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 550-1900

**MAIL ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neothetics, Inc.
- **DATE OF NAME CHANGE:** 20140905

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 24, 2026

**EVOFEM BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36754** | **20-8527075** |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |

---

**7770 Regents Road, Suite 113-618**

**San Diego, California 92122**

(Address of principal executive offices)

**(858) 550-1900**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement**

***Distributorship Agreement in Sub-Saharan Africa***

 ****

On April 24, 2026 (the "Effective Date"), Evofem Biosciences, Inc. (the "Company"), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company ("Clovis Davis") to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the "Territory") for a period of five years commencing on April 24, 2026.

Under the distributorship agreement, Clovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory. Local regulatory filings for approval of SOLOSEC will be based on Evofem's registration dossier submitted and approved by the U.S. FDA.

**Item 7.01 Regulation FD Disclosure**

On April 27, 2026, the Company issued a press release announcing the exclusive distributorship agreement with Clovis Davis. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The press release incorporated into this Current Report on Form 8-K includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to those regarding the anticipated reception of SOLOSEC in the Territory by healthcare providers and patients; the timing and anticipated outcomes of the reviews of the SOLOSEC MA submissions, once filed, by regulatory authorities in the Territory; and the estimated prevalence of BV and Trich and estimated addressable patient population in the Territory. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 11, 2026 and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1+ | [Exclusive Distributorship Agreement dated as of April 24, 2026](ex10-1.htm) |
| 99.1 | [Press release dated April 27, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

+ Certain schedules, exhibits, annexes and similar attachments have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EVOFEM BIOSCIENCES, INC.** | **EVOFEM BIOSCIENCES, INC.** |
| Dated: April 30, 2026 | By: | */s/ Saundra Pelletier* |
|  |  | Saundra Pelletier |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**CERTAIN CONFIDENTIAL INFORMATION INDICATED BY "[\*\*\*]" HAS BEEN OMITTED FROM**

**THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND**

**(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

**EXCLUSIVE**

**DISTRIBUTORSHIP AGREEMENT**

THIS DISTRIBUTOR AGREEMENT (this Agreement) is entered into as of April 24, 2026, by and between Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company, (hereinafter "Distributor"), located at 2518 Burnsed Blvd., Ste 610, The Villages, FL 32163 and Evofem Biosciences, Inc., a Delaware corporation (hereinafter "Evofem") located at 12636 High Bluff Dr. #400, San Diego, CA 92130.

**RECITALS**

A. Evofem
 is the manufacturer and seller of the pharmaceutical Products (as defined below) which it
 markets and sells through various distribution arrangements.

B. The
 Distributor is a distributor of pharmaceutical and related products.

C. Evofem
 and Distributor ("the Parties") have agreed to enter into this Agreement for
 the purpose of establishing an exclusive supply and distribution Agreement between them for
 the Products in the territory ("the Territory") described in Item 7 - The Territory
 of Schedule A.

**THE PARTIES AGREE AS FOLLOWS:**

**1.** **DEFINITIONS** 

1.1 In this Agreement, the following words and phrases are defined
as follows:

**"Agreement"** means this Distribution Agreement and includes all schedules and amendments to this Agreement.

**"Approval"** means all permits, licenses or approvals required from time to time to sell or distribute the Products in the Territory.

**"Confidential Information"** means all of the following: (a) the trade secrets of the Parties; (b) the names of all past, present, and prospective employees of such Party; and (c) the Party's past, present, and prospective systems, methods and procedures used in the operation of such Party's business; (d) any other oral, written, electronic and/or recorded non-public information of any Party's business, products, financial condition, operations, assets or liabilities; (e) any documentary information that is marked "Confidential", "Private", "Secret", "In Confidence" or "Not to be disclosed"; (f) all notes, analyses, summaries, compilations, studies projections, forecasts budgets, price list or records of any Party that is marked confidential or which by its nature is confidential.

Confidential Information *excludes* information that is: (a) publicly available other than as a result of a wrongful disclosure by the receiving party; (b) independently acquired or developed by a Party without breach of this Agreement; or (c) available to a Party on a non-confidential basis from a third person not bound by any confidentiality agreement or fiduciary obligation owed to the other Party.

**"Consumer"** means any individual, business, or entity that purchases or may purchase the Products for end use or resale within the Territory. This definition excludes wholesalers or distributors unless otherwise specified.

**"Deliver/Delivery"** means delivery of the Products to the Distributor's nominated warehouse in the Territory.

**"Distributorship"** means this distributorship relationship between the Parties.

 

**"Intellectual Property"** includes all forms of intellectual property rights recognized under law, whether registered or unregistered, including copyrights, trademarks, patents, designs, trade secrets, and processes. This includes rights applied for but not yet granted.

**"Invoice"** means an invoice in the form as provided by Evofem.

**"Law"** means all applicable statutes, Acts, rules, regulations and by-laws current in the United States of America and the Territory together with all amendments and replacing laws.

**"Material Breach"** means any of the following:

(a) any
breach of a clause that is described as an essential term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any
 breach of a clause that is capable of rectification and the Party in breach has failed to
 rectify within 30 days after being requested so to do by the other Party.

**"Market Conformant"** defined as Products that meet the product specifications provided by Evofem as well as the quality standards and legal requirements for sale within the U.S. and are fit for their intended purpose as defined by Good Manufacturing Practice (GMP) regulations promulgated by the U.S. Food and Drug Administration under the authority of the Federal Food, Drug and Cosmetic Act.

**"New Products"** means 1) all new products of whatever kind that Evofem introduces as part of its overall range of Products available for sale in the Territory and 2) all enhancements, upgrades, new versions and/or replacements of any of the Products and/or newly developed products of Evofem.

**"New Territory"** means all new territories, countries, and regions in Africa within which Evofem or Distributor desires to sell Evofem's products , subject to regulatory approval to sell within that New Territory.

**"Notice"** means a written communication delivered via email, facsimile, or registered mail. Notices by email are deemed received upon the sender receiving an automated read receipt or reply; notices by facsimile are deemed received upon successful transmission confirmation; notices by registered mail are deemed received seven business days after posting.

**"Order"** means an Order placed by the Distributor to Evofem for any of the Products, which Order must be in the form specified by Evofem. The Order must include details of the Products' description, the quantity ordered, the price per item in USD, the total price in USD, the requested time for Delivery and such other information as the Parties may reasonably require.

**"Party/Parties"** means the Parties to this Agreement and includes their lawful successors and assigns. Any reference to a Party will include, where applicable, any subsidiary controlled by a Party or by the same persons who control that Party.

**"Person"** includes anybody that is recognized at Law in the Territory whether it be a natural person, an entity or corporation.

**"Products"** includes all the products listed in Schedule B.

**"Quarterly"** means a period of 3 months.

**"Recommended Retail Prices"** means the prices set out in Schedule C which Evofem recommends to the Distributor as the selling price of the Products to Consumers.

**"Territory"** is defined with specific geographical boundaries as detailed in Item 7 - The Territory of Schedule A, including all major regions and any specific exclusions.

**"Term"** means the period commencing as set out in Items 5 and 6 - The Term of Schedule A unless this Agreement is terminated by either Party during that period, in which case the Term will expire on the date of such termination. The Term also includes all extensions of the Term and all other periods such as the Parties may in writing agree.

**"US $"** and **"USD"** mean United States Dollar.

**"Year"** means each period of 12 months during the Term, the first Year commencing on the date hereof and expiring on the day before the anniversary of the date hereof.

**2.** **INTERPRETATION** 

2.1 Words importing any gender include all genders including the
neuter gender.

2.2 Words importing the singular includes the plural and vice versa.

**3.** **APPOINTMENT AND TERM** 

3.1 Evofem
 appoints the Distributor, and the Distributor accepts its appointment as the exclusive distributor
 of the Products for the Term in the Territory on and subject to the rights and obligations
 of the Parties as set out in this Agreement and Schedule A.

3.2 During
 the Term, the Distributor will for so long as it is the Distributor in the Territory use
 its best efforts to market, sell, distribute and promote the Products in the Territory.

3.3 During
 the Term, each Party promises to act reasonably and in good faith towards the other and provide
 to the other on request all reasonable assistance in promoting the sale of the Products in
 the Territory. Evofem shall not be required to incur any costs in providing assistance to
 Distributor in promoting the sale of the Products in the Territory.

3.4 Subject
 to the prior written approval of Evofem, the Distributor may appoint sub-distributors, agents,
 licensees, franchisees and other representatives to market, sell and distribute the Products
 in the Territory or any part thereof. The Distributor is responsible for all acts and omissions
 of its sub-distributors, agents, licensees, franchisees and other representatives as if those
 acts or omissions were those of the Distributor with the intent that any such act or omission
 will be a breach of this Agreement by the Distributor.

3.5 During
 the Term the Distributor is not entitled to sell products that are competitive with or similar
 to the Products.

**4.** **NEW PRODUCTS & TERRITORIES** 

4.1 Evofem
 will promptly notify the Distributor of any New Products available to the Distributor.

4.2 All
 New Products which Evofem, at its sole discretion, decides to distribute, market, or sell
 in the Territory, must first be offered to the Distributor to market and sell in the Territory.
 If the Distributor does not agree to sell the New Products on the terms proposed by Evofem,
 then Evofem may make such other arrangements as it thinks fit for the marketing and sale
 of the New Products in the Territory. The Distributor will be deemed not to have agreed to
 sell the New Products if it fails to accept the terms proposed by Evofem within 30 days of
 those terms being offered to the Distributor.

4.3 All
 New Territories in which either Evofem or Distributor distribute, market, or sell Products
 must first be offered to the Distributor to market and sell Evofem Products in or for Distributor
 to offer to Evofem to sell Evofem Products in such New Territories. If the Distributor does
 not agree to sell in the New Territory(ies) on the terms proposed by Evofem, Evofem may make
 such other arrangements as it thinks fit for the marketing and sale of Products within the
 New Territory and Distributor must continue to comply with Section 3.5 above. The Distributor
 will be deemed not to have agreed to sell within the New Territory if it fails to accept
 the terms proposed by Evofem within 30 days of those terms being offered to the Distributor.
 Notwithstanding, if Evofem receives a third-party proposal to commercialize Evofem Products
 in multiple geographies that includes any in which Distributor is not active or any New Territories
 in which Distributor has not accepted Evofem's proposed terms, Evofem is free to enter
 into such agreement without prior notice to Distributor.

**5.** **INTELLECTUAL PROPERTY AND CONFIDENTIAL INFORMATION** 

5.1 Evofem
 is the exclusive owner of all of Evofem's Intellectual Property, including Evofem's
 Intellectual Property in the Products. The Distributor will not challenge or dispute Evofem's
 ownership of Evofem's Intellectual Property. The Distributor will not do anything or
 omit to do anything which could detrimentally affect the ownership of Evofem's Intellectual
 Property.

5.2 The
 Distributor is granted an exclusive, non-transferable license to use Evofem's trademarks
 and associated intellectual property solely for the purposes of marketing, selling, and distributing
 the Products within the Territory, except that Distributor shall be authorized to transfer
 such licenses to any Evofem approved sub-distributors, agents, licensees, franchisees, and
 other representatives, in order for them to market, sell, and distributor Products within
 the Territory. This license does not extend to any other use without prior written consent
 from Evofem.

5.3 Each
 Party, acting as the Receiving party agrees to (a) Maintain the confidentiality of the Disclosing
 Party's Confidential Information and use the same degree of care to protect such Confidential
 Information as it uses to protect its own confidential information, but in no event less
 than reasonable care; (b) Use the Disclosing Party's Confidential Information solely
 for the purpose of fulfilling its obligations under this Agreement; (c) Not disclose the
 Disclosing Party's Confidential Information to any third party without the prior written
 consent of the Disclosing Party, except to the Receiving Party's employees, agents,
 or subcontractors who need to know such information for the purposes of this Agreement and
 who are bound by confidentiality obligations at least as restrictive as those in this Agreement;
 and, (d) Promptly notify the Disclosing Party of any unauthorized use or disclosure of Confidential
 Information and cooperate with the Disclosing Party to mitigate the effects of any such unauthorized
 use or disclosure.

5.3.1 Return
 or Destruction of Confidential Information: Upon termination or expiration of this Agreement,
 or upon the Disclosing Party's written request, the Receiving Party shall promptly
 return or destroy all copies of the Disclosing Party's Confidential Information in
 its possession or control and certify in writing that it has done so, except that the Receiving
 Party may retain one copy of the Confidential Information in its legal files for compliance
 purposes only and provided that such copy of the Confidential Information remains subject
 to the terms, conditions and restrictions of this Section 5.3.

5.3.2 Survival:
 The obligations of confidentiality under this Section 5 shall survive the termination or
 expiration of this Agreement for a period of three (3) years, at which time the one retained
 copy specified in 5.3.1 will be destroyed and documentation of such destruction provided
 by the Receiving Party to the Providing Party.

**6.** **EVOFEM'S OBLIGATIONS** 

6.1 Evofem
 will provide the Distributor with suitable promotional and marketing materials, in digital
 format and in English, in relation to the Products throughout the Term. If the Distributor
 chooses to use these materials, then by this subclause, it is licensed to do so and at no
 fee. There is no obligation on Evofem to modify or adapt any of the materials it provides
 to the Distributor. Distributor will be solely responsible for translation, printing, etc.
 of the promotional and marketing materials. Translation of the labeling must be conducted
 by a licensed translator, approved by the appropriate regulatory body in the Territory, and
 all translations must be provided to Evofem for review and approval prior to first use. If
 additional materials are required to be developed, such development will be at Distributor's
 sole cost and expense. Any third-party materials developed will be subject to Evofem's
 review and prior approval.

6.2 Evofem
 undertakes to promptly attend to the reasonable fulfilment of all Orders for the Products
 and their Delivery in accordance with the terms of this Agreement and subject to proper arrangements
 acceptable to Evofem being made for payment. The Distributor acknowledges that Evofem's
 ability to fulfil orders is dependent on available stock of the Products Ordered as well
 as manufacturing schedules, availability of raw materials and other supply chain logistics,
 which are not under Evofem's direct control.

6.3 Evofem
 undertakes to the Distributor to endeavor to maintain sufficient quantities of the stock
 of the Products so as to reasonably be able to meet the Distributor's anticipated Orders
 having regard to forecasts provided to Evofem by the Distributor.

6.4 **[\*\*\*]** 

6.5 Evofem
 must provide all Patient Package Inserts and Instructions for Use required for use of the
 Products by Consumers in English. Distributor must provide translated Patient Package Inserts
 and Instructions for Use if required by any Regulatory Authority in accordance with Section
 6.1 above.

**7.** **PRODUCT DEFECTS & GENERAL LIABILITY** 

7.1 Evofem warrants to the Distributor that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Products and their packaging at the time of shipment will be fit and Market Conformant at that time; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if any Product and/or its packaging is damaged or not Market Conformant, and such damage or non-Market Conformance was not apparent upon delivery or reasonably discoverable in the initial fourteen (14) day inspection window as set out in Section 12.4 below, and was not caused as a result of shipping/transport, for which Distributor is responsible, and provided the Distributor has stored the Product in question in accordance with the USPI and as noted in Schedule D, and provided no "use by date" has expired and the Product is not within three (3) months of its "use by date" and the Distributor has not altered, tampered with, or adulterated the Product and/or its packaging, then:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Evofem must either replace or pay the cost of replacing the defective Product as determined by Evofem at its sole discretion on a case-by-case basis and at its own cost, and bear the cost of the defective Product destruction within the Territory under oversight of Distributor, with certification of destruction as applicable; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) where the defect is confined to the Product's packaging, Evofem shall at its own expense:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) repackage
 the affected Product. The Distributor shall undertake and coordinate in facilitating the
 return of affected Product for repackaging.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) If
 the defect in the packaging is minor and assessed not to pose any risk to safety or efficacy,
 Evofem may issue a formal declaration confirming that the Product contained therein remains
 safe for use. In such case, Evofem shall commit to rectifying this defect in all subsequent
 batches of the Product that have not yet been produced. This declaration shall be provided
 to the Distributor in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) in the event the U.S. Food and Drug Administration (FDA) or any regulatory authority in the Territory issues a recall or withdrawal of any Product, or if Evofem determines a recall is necessary or advisable, Evofem shall promptly notify Distributor in writing of such recall, specifying the reasons for the recall and the actions to be taken by both Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Distributor shall notify Evofem immediately upon becoming aware of any event, incident, or circumstance that could lead to a recall, market withdrawal, or safety alert regarding any Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Upon receipt of a recall notification from Evofem, Distributor shall immediately cease all distribution and sale of the recalled product and quarantine all existing inventory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Distributor shall cooperate fully with Evofem in the recall process, including but not limited to the authorized destruction of recalled Products, providing all necessary information for Evofem to account for all distributed Products and assisting in notifying Consumers of the recall.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Evofem shall bear all actual, reasonable, and documented costs and expenses associated with the recall, including, but not limited to, the costs of notification, and destruction of recalled Product, unless the recall is due to the actions, inactions, negligence, willful misconduct, or breach of this Agreement by Distributor, or its Agents.

7.2 Evofem
 represents to the Distributor that all Patient Package Inserts and Instructions for Use and
 any promotional or marketing materials provided by Evofem with the Products will be provided
 in English, are up to date, and will be updated as appropriate. Furthermore, such materials
 do not contain any representations that are incorrect, untrue, deceptive, or misleading,
 or are likely to deceive or mislead the Distributor or any Consumer.

7.3 The
 Distributor must follow all directions and carry out all requests of Evofem in respect to
 the storage, packaging, and presentation of the Product. If the Distributor requests any
 particular packaging or presentation to meet the applicable laws of any country in the Territory,
 then the costs thereof must be borne by the Distributor and Distributor may only sell such
 Product in the country in the Territory for which it is labeled. Distributor shall consult
 with Evofem to ensure that Evofem's manufacturer(s) can comply with any such requirements
 and Evofem may at its discretion require prepayment by the Distributor of this cost as a
 pre-condition to such packaging and/or presentation being carried out. If Evofem's
 manufacturers cannot reasonably meet the requirements of any specific country, territory,
 or region in the Territory, then Distributor must make its own arrangements, at Distributor's
 sole cost and expense, to ensure that the Products meet all such requirements prior to Distributor
 marketing or selling any Products in such country, territory or region.

7.4 Neither
 Party will in the course of conducting its business engage in conduct which constitutes a
 breach of any Law or regulation and in the case of Distributor, Distributor will not conduct
 its business or engage in any conduct that constitutes a breach of any law of the Territory.
 This is an essential term.

7.5 If
 either Party negligently or intentionally does anything or omits to do anything which has
 the effect or consequence of rendering the other Party liable to any third party or Consumer
 under any Law of the U.S. and in the case of any negligent action or inaction by Distributor
 which has the effect or consequence of rendering Evofem liable to any third party or Consumer
 under any Law, then the Party whose act or failure to act has caused such liability fully
 indemnifies the other Party against all liabilities, losses, damages and other claims that
 it might thereby incur.

7.6 Except
 in the event of gross negligence, intentional misconduct or any breach of Section 5.3, neither
 Party shall have any liability for lost profits or revenue or any incidental, consequential,
 special, punitive, or exemplary damages howsoever arising, including but not limited to by
 breach of such Party's negligence.

**8.** **DISTRIBUTOR'S OBLIGATIONS AND COVENANT NOT TO COMPETE** 

8.1 The
 Distributor will use its best efforts to promote, market, distribute and sell the Products
 within the Territory so as to maximize the sale of the Products within the Territory during
 the Term. The Distributor must not make or publish any disparaging remarks or comments about
 the Products or Evofem. This is an essential term.

8.2 The
 Distributor must not distribute the Products outside of the Territory or sell or supply the
 Products to any other Person or Party to sell or distribute outside the Territory without
 Evofem's prior written consent. This is an essential term.

8.3 The
 Distributor is entitled to lawfully market the Products as it deems fit in the Territory
 and may enter into such lawful agreements as it deems desirable to market and/or promote
 the Product in the Territory.

8.4 The
 Distributor will maintain a database of all complaints, comments or claims made to it in
 respect to the Products from Consumers and will provide Evofem with these details on at least
 a monthly basis. Distributor must also comply with all reporting requirements of the Safety
 Data Exchange Agreement (SDEA) between Evofem and the Distributor. This is an essential term.

8.5 The
 Distributor will be responsible for its own storage of the Products and shall comply with
 Evofem's recommendations for storage.

8.6 The
 Distributor may use Evofem's Intellectual Property, including its trademarks, for the
 sole purpose of advertising and marketing of the Products and in its promotional material
 for the Products in accordance with the terms of this Agreement but for no other purposes.
 This is an essential term.

8.7 The
 Distributor will not intentionally deface, obscure, or remove from any of the Products Evofem's
 trademarks or reservations of Intellectual Property. This is an essential term.

8.8 The
 Distributor is solely responsible for and must at its expense obtain all any necessary approvals,
 licenses, permits, authorizations, and certifications for the Products to enable it to market
 and sell the Products in the Territory including, if applicable, any certification or any
 other regulatory body's requirements for the sale, distribution, marketing or use of
 the Products in the Territory or part thereof. Evofem will provide reasonable assistance
 and cooperation in respect of such approvals. If any specific attestations or certifications
 are required to be created as part of the regulatory process to enable Distributor to market
 and sell the Product in the Territory, Distributor shall provide such to Evofem in final
 form for Evofem's review, signature, and stamp (if required). If Evofem is required
 by any regulatory body in the Territory to provide a Certificate of Pharmaceutical Product
 (CPP) for any Product, Distributor shall bear all costs related to obtaining, authenticating
 and/or attesting such CPP.

8.9 Because
 Distributor will be required to obtain registrations of the Products in the Territory during
 the Term of this Agreement, the Parties will delineate responsibilities of each Party concerning
 the registration process, including any associated costs and timelines, in an addendum to
 this Agreement . This addendum must be agreed upon in writing and signed by both Parties
 before any registration activities commence. Any registrations obtained by Distributor shall
 be transferred to Evofem or any designee of Evofem upon the expiry or termination of this
 Agreement.

8.10 The
 Distributor has no authority to make any representation on behalf of Evofem or any representation
 relating to any of the Products not provided by Evofem. This is an essential term.

8.11 During
 the Term the Distributor must not directly or indirectly sell, market, or distribute products
 that are similar to or competitive with the Products. It will be a breach of this clause
 for any director or shareholder of the Distributor to have an interest directly or indirectly
 in any company or business that sells, markets, or distributes the same or similar products
 to the Products or any competing products (any product that is approved to treat bacterial
 vaginosis or trichomoniasis). This is an essential term.

8.12 The
 Distributor acknowledges and agrees that at the end of the Term the Distributor will hold
 the goodwill of its business of selling the Products exclusively on trust for Evofem and
 for any new distributor nominated by Evofem to distribute the Products in the Territory.

8.13 Performance
 Obligations

8.13.1 Ensuring
 timely payments for all Products purchased in accordance with the payment terms set forth
 in this Agreement. This is an essential term.

8.13.2 Providing quarterly and cumulative yearly performance reports
to Evofem, detailing sales figures, market conditions, promotional activities, and forecasts. This is an essential term.

**9.** **SUB DISTRIBUTORS** 

9.1 The
 Distributor may appoint sub-distributors, licensees and franchisees for the marketing, sale,
 distribution and/or maintenance of the Products in the Territory. The Distributor must obtain
 Evofem's prior written consent before appointing any sub-distributors, licensees or
 franchisees and all sub-distributors, licenses and franchisees must agree to comply with
 the terms of this Agreement. The Distributor remains liable for all acts and omissions of
 its sub-distributors, franchisees, and licensees as if they were the Distributor's
 own acts or omissions.

9.3 The
 Distributor must ensure that any Person or Party it appoints as a sub-distributor, licensee,
 or franchisee is a Person or Party of good repute and character with suitable experience
 and training capabilities to act as a sub-distributor, licensee, or franchisee of the Products
 within the Territory.

9.4 The
 Distributor will be exclusively responsible for all of the acts or omissions of its sub-distributor
 (s), the franchisee(s) and sub-licensee (s) in respect of the Products and indemnifies and
 keeps indemnified Evofem against all liabilities and/or losses sustained as a consequence
 of any negligent, improper or unlawful conduct and/or omission by any sub-distributor(s),
 licensee(s) or franchisee(s).

9.5 No
 agreement between the Distributor and any sub-distributor, licensee, or franchisee shall
 be for any period exceeding the Term.

9.6 No
 agreement between the Distributor and any sub-distributor, licensee, or franchisee will be
 binding on Evofem or directly or indirectly impose any obligation on Evofem.

9.7 The
 Distributor must promptly on request provide Evofem with a copy of every sub-distribution,
 license, or franchise agreement it enters into. None of the terms of such agreements shall
 be inconsistent with this Agreement.

**10.** **INSURANCE** 

10.1 The
 Distributor is required to maintain product liability insurance with coverage that is appropriate
 and sufficient to cover all potential liabilities related to the Products but not in amount
 of less than U.S. $1,000,000 per occurrence and U.S. $3,000,000 in the aggregate including
 coverage for bodily injury (including wrongful death), product liability, product recall
 and completed operations, for the entire duration of the Term and for three (3) years following
 its conclusion. This insurance must be maintained with a reputable insurer and must meet
 minimum coverage requirements.

10.2 The
 Distributor shall provide Evofem with current certificates of insurance as proof of such
 coverage:

10.2.1 Prior
 to the commencement of the Term

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2.2 Annually
 thereafter, no later than 30 days following the expiration of the previous coverage period.

10.2.3 Upon
 Evofem's request at any time, to which response must be provided within 14 days of
 the request.

10.3 Distributor
 warrants to Evofem that it will not do or omit to do any act or thing that could cause any
 insurance coverage to be jeopardized in any way.

10.4 Distributor
 will name Evofem as an additional insured under the policies specified in Section 10.1 above
 and each policy shall provide at least thirty (30) days written notice to Evofem prior to
 cancellation.

**11.** **[\*\*\*]** 

**12.** **DELIVERY OF PRODUCTS** 

12.1 Evofem
 must Deliver the Products so Ordered by the Distributor to the Distributor on INCOTERMS as
 stipulated in Schedule A.

12.2 The
 Distributor covenants that it will bear all the costs and charges arising out of the shipping
 of the Products from Evofem's warehouse as well as the costs and charges of any Customs
 Clearance, duties, tariffs and taxes and transportation of the Products to the final warehouse,
 subject to INCOTERMS as stipulated in Schedule A. Title to the Products and risk of loss
 shall pass to Distributor upon the Products being tendered to the carrier at the shipper's
 dock.

12.3 Where
 the Products may be hazardous, flammable, or fragile, Evofem must ensure they are packaged
 and labelled in accordance with all regulations relating to hazardous air/sea/overland transportation
 Laws for the shipment and/or transportation of such Products from Evofem to the place of
 delivery.

12.4 Upon
 Delivery of the Products, the Distributor must promptly visually inspect the Products and
 within 14 days of such receipt give Evofem Notice of any Products that are apparent from
 such inspection to be not of Market Conformant Quality (and not resulting from any damage
 incurred during shipping) and the Distributor will arrange for such Products to be returned
 to Evofem at Evofem's expense. If no Notice is given in that time-frame, the Products
 will be deemed to be Market Conformant and fit for purpose except in respect to any latent
 defects not reasonably apparent on inspection.

12.5 Where
 a visual inspection of the Products will not disclose any relevant defect then the Distributor
 must promptly notify Evofem of such defect when it becomes aware of its existence and such
 defect will be addressed in accordance with Section 7.1 above.

**13.** **TERMINATION** 

13.1 This
 Agreement may be terminated by either Party if the other Party commits a Material Breach.
 The procedure for termination is set out in this Clause.

13.2 On
 termination (except in the event of a termination by Evofem due to a breach by Distributor)
 Evofem must either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Deliver sufficient quantities of Products Ordered by the Distributor so as to allow the Distributor to satisfy all of its outstanding contractual obligations to its Consumers, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) at its sole discretion take over responsibility for meeting all those outstanding orders, in which event Evofem shall bear all responsibility for those Consumers in respect to those outstanding Orders.

13.3 It
 will be a breach of an essential term by the Distributor, and Evofem will be entitled to
 terminate this Distributorship by giving 30 days' prior Notice to that effect to the
 Distributor, if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Distributor fails to pay any amount owing to Evofem when due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Distributor becomes insolvent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Distributor commits any breach of this Agreement and fails to remedy that breach within 30 days of the date of a written request from Evofem to do so;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Distributor breaches any terms of this Agreement that is expressed to be an essential term; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Distributor ceases to carry on business.

13.4 It
 will be a breach of an essential term by Evofem, and the Distributor will be entitled to
 terminate this Distributorship by giving 30 days' prior Notice to that effect to Evofem,
 if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Evofem fails to Deliver any of the Products to the Distributor within 30 days of the delivery date specified in the Order for Delivery which has been accepted by Evofem in writing and the Distributor has requested in writing such Delivery and that Delivery has not been made within those 30 days, barring any delays that may related to or arise from any required changes to packaging / label;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Evofem fails to make any payment due by it to the Distributor within 30 days of being requested by the Distributor in writing to make such payment as required including, but not be limited to, the terms as described in 7.1.b.i, 7.1.c.iv;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evofem commits any breach of this Agreement and fails to remedy that breach within 30 days of being requested by the Distributor to remedy that breach;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Evofem ceases to carry on business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Evofem ceases to supply any of the Products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) There is a substantial governmental mandated product recall of any of the Products in the Territory;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) It becomes unlawful to sell the Products or any part of them in the Territory;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Evofem breaches any term of this Agreement that is expressed to be an essential term.

13.5 Notwithstanding
 anything elsewhere contained in this Agreement and without giving any Notice under this clause,
 either Party may terminate this Distributorship immediately by giving Notice to the other
 Party if the recipient Party of such Notice has breached any law then applying to this Agreement
 or does any act or omits to do any act that could cause the terminating Party to be in breach
 of any law applicable to this Agreement or wrongfully and knowingly uses or discloses the
 terminating Party's Confidential Information to any third party.

13.6 Upon
 termination, each of the Parties must promptly return to each other all Confidential Information
 and Intellectual Property belonging to the other Party within thirty (30) days of such termination
 date and with certification of destruction as applicable. Where such Confidential Information
 is incapable of being returned in tangible form then each Party warrants to the other that
 it will destroy all electronic records of such Confidential Information within thirty (30)
 days and with certification of destruction as applicable. In addition, the Distributor will
 return to Evofem or, if required by Evofem, destroy any point-of-sale displays and other
 marketing materials provided to the Distributor by Evofem, if any within thirty (30) days
 and with certification of destruction as applicable.

13.7 Notwithstanding
 termination of the Distributorship, this Agreement will continue to be binding on the Parties
 and fully enforceable in respect to the rights and obligations of each Party relating to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the payment of any sum;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any continuing obligations to any Consumers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Product warranty to Consumers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Confidential Information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) return of property and transfer of trademarks and Intellectual Property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) obligations in this Clause and otherwise in this Agreement that are expressly intended to apply after termination.

13.8 On termination of the Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Distributor will promptly notify Evofem of all stock of the Products which it has, and which are not required by it to fulfil outstanding contractual obligations to Consumers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Within 14 days thereafter, Evofem may elect (but is not obliged) to buy back all commercial inventory of the Products held by the Distributor which the Distributor is not contractually obliged to sell to its Consumers. The price Evofem will pay for the buyback of commercial inventory will be the price paid by the Distributor for the commercial inventory plus 10% less all set offs (if any) of amounts owing by the Distributor to Evofem. Nothing in this paragraph obliges Evofem to buy back commercial inventory that is unfit for sale or that has been damaged. Damage includes damage to packaging.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Distributor must, subject to this Agreement, meet all its outstanding contractual obligations in any respect of its Consumers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If within 14 days of termination Evofem has not purchased all the stock of the Products held by the Distributor, then notwithstanding anything else where contained the Distributor will be entitled to sell all its remaining commercial inventory of the Products in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event of Evofem buying back the commercial inventory of the Products from the Distributor, Evofem will pay (less any set offs) the Distributor for all such stock bought back and take delivery thereof at the date and time of payment. Delivery will be at the place where the stock is stored by the Distributor.

**14. RELATIONSHIP**

14.1 The
 Parties acknowledge that they are not in partnership, there is no joint venture between them
 or franchise arrangement, and that the only relationship between them is that of seller in
 the case of Evofem and buyer in the case of the Distributor in respect of the Products on
 the terms in this Distribution Agreement. Neither Party shall claim or hold itself out as
 having any other relationship, authority, right or entitlement to represent or act as agent
 of the other or to have any interest or shareholding in the other.

14.2 The
 Distributor sells the Products to Consumers as principal, not as agent for Evofem.

14.3 It
 is expressly agreed that nothing in this Agreement gives rise to any fiduciary relationships
 between Evofem and the Distributor and no Party owes any fiduciary duty to the other in respect
 of its conduct.

14.4 It
 is expressly acknowledged that nothing in this Agreement confers upon Evofem the right to
 direct the Distributor to conduct its business in any particular way. The Distributor acknowledges
 that it has not paid any premium or other sum as consideration for entering into this Agreement
 nor has it been required as a precondition to entering into this Agreement to purchase any
 Product or pay for any training or other services.

**15.** **DISPUTE RESOLUTION AND JURISDICTION** 

15.1 It
 is agreed by the Parties that this Agreement will be construed in accordance with the Law
 of the United States and each Party covenants that it submits to the sole and exclusive jurisdiction
 of the Courts, both state and federal, of Delaware, USA for the resolution of any dispute
 under the Agreement.

15.2 The Parties will comply with the following dispute resolution
procedure:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) where a dispute arises between the Parties, the complainant Party will set out in writing and in English what it regards the dispute to be, telling the respondent Party:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the nature of the dispute; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) what outcome the complainant wants;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) what action the complainant Party requires in order to settle the dispute.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) both Parties will make every effort to resolve the dispute informally through negotiation and will in so doing act in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) for mediation under this Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if the Parties cannot agree under sub clause (b) within seven (7) days, either Party may refer the matter to a mediator; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if the Parties cannot agree about who should be the mediator, either Party may ask the American Arbitration Association to act as the mediator and that mediator will act as mediator of the dispute;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the mediator may decide the time and place for mediation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the
 Parties or their legal representative(s) must attend the mediation either in person or via
 virtual communications platform and try in good faith to resolve the dispute through mediation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the
 Parties are equally liable for the costs of mediation and the costs of the mediator under
 this part unless they agree otherwise. The Parties must pay their own costs for attending
 at or being represented at the mediation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) nothing
 in this clause affects the right of a Party to take legal proceedings under this Agreement,
 if mediation fails to resolve the dispute;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) nothing
 contained in the dispute resolution procedures above will deny from or delay any Party seeking
 immediate injunctive relief from an appropriate Court where in the reasonable opinion of
 the Party the failure to obtain such relief would cause irreparable damage to the Party concerned;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) these
 dispute resolution procedures will not apply to events giving rise to a right of termination
 of this Agreement where there is no legitimate dispute as to the occurrence of that event.

**16.** **NOTICES** 

16.1 Each
 Party choose the address set out in the preamble of this Agreement, at which address all
 notices and pleadings in connection with this Agreement, or any other action arising therefrom,
 must effectively be served.

16.2 Any notice that is given to one Party by the other, which:

16.2.1 is
 personally delivered to the Party's address will be construed to be received on the
 date of delivery, unless the contrary is proven.

16.2.2 is
 sent by prepaid registered post, to a Party's address will be construed to be received
 after seven (7) days after the posting of such, unless the contrary is proven.

16.2.3 is
 sent via electronic mail to the email address listed as the Managing Director in Schedule
 A, with affirmative acknowledgement of receipt.

16.3 Each
 Party is entitled by means of written notice to the other Party to change its address

**17.** **General** 

17.1 The
 Parties agree to perform all actions that may be necessary for the proper execution of all
 the terms of this Agreement.

17.2 Each
 Party warrants to the other Party that it has power, authority and legal right to sign and
 perform this Agreement and that this Agreement has been duly authorized by all necessary
 actions of its directors and constitutes valid and binding obligations on it, in accordance
 with the terms of this Agreement.

17.3 This
 Agreement constitutes the full agreement between the Parties and no guarantees, warranties
 or any other stipulations and terms of whatever nature which are not contained in this Agreement,
 will be binding on the Parties.

17.4 No
 amendments, alterations of or additions to the provisions and terms of this Agreement or
 any mutual cancellation thereof, will be of any cause or effect, unless reduced to writing
 and signed by both Parties.

17.5 No
 indulgence offered by any Party to the other Party will be construed as a waiver of the waiving
 Party's rights and the latter Party will not be entitled to enforce any such indulgences
 whether such indulgences occurred in the past or may occur in the future.

**18.** **FORCE MAJEURE** 

Except for obligations to make payment, non-performance by any Party will be excused to the extent that performance is rendered impossible or impractical by acts of God, lighting strike, earthquakes, floods, storms, explosions, fires and any natural disaster, acts of war, acts of public enemies, terrorism, riots, civil commotion, malicious damage, sabotage and revolution or governmental acts or orders or restrictions.

**19.** **SEVERABILITY** 

If any clause of this Agreement is invalid under any applicable such Law, the clause will be limited, narrowed, construed, or altered as necessary to render it valid, but only to the extent necessary to achieve such validity. If necessary, the invalid clause will be deleted from the Agreement and the remaining clauses will remain in full force and effect.

**20.** **COUNTERPARTS** 

This Agreement may be executed in counterparts, each of which will be deemed to be an original and all of which together will constitute one instrument and Agreement.

**21.** **NO THIRD-PARTY BENEFICIARIES** 

This Agreement is entered into for the benefit of the Parties and may not be deemed to grant any rights or interests to any third party.

**22.** **LEGAL ADVICE** 

Each Party acknowledges and represents to each other that it has had the opportunity to seek and obtain separate and independent legal advice before entering into this Agreement. If either Party has entered this Agreement without first taking legal advice, it has done so at its sole and absolute discretion, and it will not be entitled to rely upon the absence of legal advice as a defense to any breach of any of the clauses of this Agreement.

**23.** **GOOD STANDING AND OFAC COMPLIANCE** 

Each Party represents and warrants that it is duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation of formation, and each Party agrees to maintain its good standing status throughout the term of this Agreement.

23.1 Each
 Party represents and warrants that neither it nor any of its directors, officers, employees
 or agents:

23.1.1 is
 currently subject to any sanctions administered or enforced ty the U.S. Department of the
 Treasury's Office of Foreign Assets Control (OFAC) or any other applicable sanctions
 authority.

23.1.2 is
 located, organized, or resident in a country or territory that is subject of comprehensive
 sanctions administered by OFAC.

23.1.3 is
 identified on the Specially Designated Nationals and Blocked Persons List (SDN List) maintained
 by OFAC, or any other similar list maintained by any other applicable sanctions authority.

23.1.4 has knowingly engaged in any transactions or dealings with,
or for the benefit of, any persons or entities identified on the SDN List, or any other similar list maintained by any other applicable
sanctions authority.

23.1.5 Each
 Party agrees to promptly notify the other Party in writing if it becomes subject to any sanctions
 or if it is otherwise in breach of any of the representations and warranties set forth in
 this clause. Upon receiving such notice or otherwise becoming aware of such circumstances,
 the other Party shall have the right to terminate this Agreement immediately upon written
 notice.

**24.** **COMPLIANCE WITH LAW** 

Both Parties agree to comply with all applicable federal, state, and local laws, regulations, and ordinances in the performance of their obligations under this Agreement.

24.1 Import
 and Export Laws: Each Party shall be responsible for complying with all applicable import
 and export laws and regulations, including obtaining all necessary licenses and permits.
 Evofem shall provide all necessary documentation to assist the Distributor in this regard.

24.2 Anti-Bribery
 and Anti-Corruption: Both Parties shall comply with all applicable anti-bribery and anti-corruption
 laws, including but not limited to the U.S. Foreign Corrupt Practices Act (FCPA) and the
 UK Bribery Act. Neither Party shall offer, give, or receive any bribes, including in relation
 to government officials or employees of private companies, to secure an improper advantage.

24.3 Data
 Protection and Privacy: Both Parties shall comply with all applicable data protection and
 privacy laws, including but not limited to the General Data Protection Regulation (GDPR)
 in the European Union and the California Consumer Privacy Act (CCPA) in the United States.
 Each Party shall ensure that personal data is processed lawfully, fairly, and transparently.

24.4 Environmental
 Compliance: Both Parties shall comply with all applicable environmental laws and regulations.
 The Distributor shall ensure that the disposal of any waste or hazardous materials complies
 with all applicable environmental laws and regulations.

24.5 Labor
 and Employment Laws: Both Parties shall comply with all applicable labor and employment laws,
 including but not limited to those relating to wages, working hours, equal opportunity, and
 workplace safety. Neither Party shall employ child labor or forced labor.

24.6 Reporting
 Requirements: Each Party agrees to promptly notify the other Party of any actual or suspected
 breach of this Section 24. Upon request, each Party shall provide the other Party with reasonable
 documentation to demonstrate compliance with this Section 24.

24.7 Remedies
 for Non-Compliance: In the event of any breach of this Section 24, the non-breaching Party
 may terminate this Agreement immediately upon written Notice to the breaching Party, and
 the breaching Party shall indemnify the non-breaching Party for any losses, damages, or expenses
 incurred as a result of such breach.

**25.** **INDEMNIFICATION BY DISTRIBUTOR** 

Distributor agrees to defend, indemnify and hold harmless Evofem and its officers, directors, employees, agents, representatives, successors and assigns from and against any and all claims, damages, liabilities, losses, judgments, penalties, costs and expenses (including without limitation attorneys' fees) directly arising out of or directly resulting from (i) any negligent or intentional acts or omissions of distributor or any of its directors, officers, employees, subcontractors, representatives, distributors, stockholders, partners, licensees, franchisees or agents, (ii) Distributor's performance pursuant to this Agreement, including in the sales and referrals of the Products, (iii) any incorrect or misleading information provided by Distributor in respect to the Products, (iv) any alteration of the Products by distributor, or (v) violation of applicable law by, Distributor or any of its directors, officers, employees, subcontractors, representatives, distributors, stockholders, partners, licensees, franchisees or agents, whether or not constituting a breach of any of the provisions of this Agreement.

**26.** **INDEMINIFICATION BY EVOFEM** 

Evofem will defend, indemnify and hold harmless the Distributor and its officers, directors, employees, agents, representatives, successors and assigns from and against any and all damage, liability, loss, judgment, penalty, cost and expense (including without limitation attorneys' fees) to the extent arising directly out of or resulting directly from an action or proceeding brought by a third party alleging that Evofem's trademarks and/or any Products sold to Distributor infringe its U.S. patent, trademark or copyright. If the use or sale of any Products furnished under this Agreement is enjoined as a result of such an action or proceeding, Evofem, at its sole cost and expense, shall either obtain on behalf of the Distributor the right to continue to use or sell such Products, substitute an equivalent Product reasonably acceptable to Distributor in its place, or reimburse Distributor the purchase price of the Products. Evofem will further defend, indemnify, and hold harmless the Distributor and its officers, directors, employees, agents, representatives, successors and assigns from and against any and all damage, liability, loss, judgment, penalty, cost and expense (including without limitation attorneys' fees) to the extent arising directly out of or resulting directly from, (i) any incorrect or misleading information provided by Evofem in respect to the use of the Products, (iii) faulty or defective Products manufactured by or for Evofem, or (iv) any negligent or intentional acts or omissions of Evofem or any of its directors, officers, employees, subcontractors, representatives, distributors, stockholders, partners or agents, whether or not constituting a breach of any of the provisions of this Agreement.

Notwithstanding anything herein to the contrary, when the Products reach the Distributor's warehouse, Distributor acknowledges that it is obliged to follow the U.S. Food and Drug Administration ("FDA") standards with respect to proper storage and subsequent transportation of the Products and that Distributor is responsible for, and Evofem's indemnification obligations shall not apply to, any damages to the Products to the extent arising from Distributor's improper storage and/or transportation thereof.

**27.** **Limitation of Liability** 

27.1 No
 Consequential Damages: Except as otherwise expressly provided in this Agreement, neither
 Party shall be liable to the other for any indirect, incidental, special, punitive, or consequential
 damages, including but not limited to loss of profits, revenue, business opportunities, or
 reputation, arising out of or in connection with this Agreement, regardless of whether such
 damages were foreseeable or whether the Party has been advised of the possibility of such
 damages.

27.2 Direct
 Damages: Each Party's liability to the other for any claims arising out of or in connection
 with this Agreement shall be limited to direct damages only and shall not exceed the greater
 of (i) the total amount paid by the Distributor to Evofem under this Agreement during the
 twelve (12) months preceding the date on which the claim arose, or (ii) five hundred thousand
 U.S. dollars ($500,000).

27.3 Exceptions
 to Limitations: The limitations of liability set forth in this Section 27 shall not apply
 to (i) damages arising from the gross negligence or willful misconduct of a Party; (ii) damages
 arising from a Party's breach of its confidentiality obligations; (iii) damages arising
 from a Party's indemnification obligations under this Agreement; or (iv) any liability
 which cannot be excluded or limited by applicable law. The maximum liability for any claims
 arising pursuant to Sections 27.3(i) – (iii) shall in no event exceed such Party's
 insurance limits for such claims, in amounts at least as mandated by this agreement.

27.4 Survival:
 The provisions of this Section 27 shall survive the termination or expiration of this Agreement.

Signed on this the 24 day of April, 2026.

Executed by: **Clovis Davis Pharmaceuticals, LLC**

---

| |
|:---|
| /s/ Jeff Reichman |
| <br>Authorized Representative<br> Name: Jeff Reichman<br> Position: Chief Operating Officer |

---

Executed by: **EVOFEM BIOSCIENCES, INC.**

---

| |
|:---|
| /s/ Saundra Pelletier |
| <br>Authorized Representative<br> Name: Saundra Pelletier<br> Position: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa**

***— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —***

 ****

SAN DIEGO, CA, April 27, 2026 — Women's health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory).

SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in females 12 years of age and older and to treat Trichomoniasis (Trich), a common sexually transmitted infection (STI), in people 12 years of age and older.

"Women everywhere deserve access to effective drugs that treat common sexual health conditions with simple, patient-friendly dosing regimens. We are delighted that Clovis Davis will distribute SOLOSEC—Evofem's single-dose oral treatment for BV and Trich—in Africa, greatly increasing its global reach," said Saundra Pelletier, Chief Executive Officer of Evofem.

"We believe SOLOSEC will be well received among healthcare providers and patients in our target markets because it delivers a complete treatment for BV and Trich with just one oral dose, enabling patients to quickly resume their normal, daily lives," said Jeff Reichman, Chief Operating Officer of Clovis Davis. "In parallel with SOLOSEC distribution, Clovis Davis is developing comprehensive women's health initiatives in Ethiopia and Uganda beginning with the OSOM® <u>BVBlue</u>® test, an FDA-cleared and CLIA-waived innovative point-of-care diagnostic test that enables rapid, accurate detection of bacterial vaginosis in clinical settings. This aligns with our commitment to not only treat, but also to improve early detection and diagnosis of BV in underserved markets where access to laboratory infrastructure may be limited."

BV is estimated to affect 25% of women in sub-Saharan Africa1. In Ethiopia alone, of the 43.8 million women aged 12 years and older2, 10.9 million women may be eligible for treatment with SOLOSEC.

Trichomoniasis is caused by the parasite *Trichomonas vaginalis*; successful resolution of this common STI requires testing and a complete course of antibiotic treatment of all infected partners. Per the World Health Organization (WHO), there were an estimated 156 million new cases of Trichomoniasis among people aged 15–49 years old in 2020 (73.7 million in females and 82.6 million in males). Approximately one third of new infections in this age group occur in the WHO African Region.3

Clovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory. Local regulatory filings for approval of SOLOSEC will be based on Evofem's registration dossier submitted and approved by the U.S. FDA.

**About Evofem Biosciences**

Evofem Biosciences, Inc. is commercializing two FDA-approved sexual and reproductive health products:

● PHEXX®
 (lactic acid, citric acid, and potassium bitartrate)– the first and only hormone-free,
 on-demand prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important
 safety information.

● SOLOSEC®
 (secnidazole) 2 g oral granules– an FDA-approved oral antibiotic for the treatment
 of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females
 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI),
 in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just
 one dose. Visit solosec.com to learn more and for important safety information.

*PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.*

**About Clovis Davis Pharmaceuticals**

Clovis Davis Pharmaceuticals, LLC, is dedicated to delivering sustainable global solutions in the production and distribution of pharmaceuticals, radioisotopes, and diagnostic tests, addressing the dynamic challenges of today's healthcare landscape. Its services are at the forefront of innovation in human and veterinary medicine, offering high-quality, cost-effective, and pioneering tests, treatments, and therapies to meet the diverse needs of healthcare providers and their patients worldwide.

**Sources**

1. Peebles
 K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial
 Vaginosis: A Systematic Review and Meta-Analysis. *Sex Transm Dis*. 2019 May;46(5):304-311.
 doi: 10.1097/OLQ.0000000000000972. PMID: 30624309.

2. United
 Nations Department of Economic and Social Affairs: Population Division. World Population
 Prospects 2024. File POP/01-3: Female population by single age, region, subregion and country,
 annually for 1950-2100 (thousands): Estimates, 1950 – 2023. Accessed 09 April 2026
 via https://population.un.org/wpp/downloads?folder=Standard%20Projections&group=Po pulation.

3. World
 Health Organization. Trichomoniasis Fact Sheet. 2025 November 21. Accessed 09 April 2026
 via https://www.who.int/news-room/fact-sheets/detail/trichomoniasis.

**Forward-Looking Statements**

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to those regarding the anticipated reception of SOLOSEC in the Territory by healthcare providers and patients; the timing and anticipated outcomes of the reviews of the SOLOSEC MA submissions, once filed, by regulatory authorities in the Territory; and the estimated prevalence of BV and Trich and estimated addressable patient population in the Territory. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 11, 2026 and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

**Contact**

For Evofem Biosciences, Inc.

Amy Raskopf, Chief Business Development Officer

araskopf@evofem.com

(917) 673-5775

For Clovis Davis Pharmaceuticals, LLC.

Jeff Reichman, Chief Operating Officer

jreichman@KKMHealthcare.com

(513) 697-8557